• FDA Approves Eylea Injection sBLA americanpharmaceuticalreview
    August 20, 2018
    Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD).
PharmaSources Customer Service